{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:00:07Z","timestamp":1790841607855,"version":"4.1.0"},"reference-count":42,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":4501,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate mechanisms underlying diabetic neuropathy progression using indexes of sural nerve morphometry obtained from two identical randomized, placebo-controlled clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Sural nerve myelinated fiber density (MFD), nerve conduction velocities (NCVs), vibration perception thresholds, clinical symptom scores, and a visual analog scale for pain were analyzed in participants with diabetic neuropathy. A loss of \u2265500 fibers\/mm2 in sural nerve MFD over 52 weeks was defined as progressing diabetic neuropathy, and a MFD loss of \u2264100 fibers\/mm2 during the same time interval as nonprogressing diabetic neuropathy. The progressing and nonprogressing cohorts were matched for baseline characteristics using an O'Brien rank-sum and baseline MFD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At 52 weeks, the progressing cohort demonstrated a 25% decrease (P &amp;lt; 0.0001) from baseline in MFD, while the nonprogressing cohort remained unchanged. MFD was not affected by active drug treatment (P = 0.87), diabetes duration (P = 0.48), age (P = 0.11), or BMI (P = 0.30). Among all variables tested, elevated triglycerides and decreased peroneal motor NCV at baseline significantly correlated with loss of MFD at 52 weeks (P = 0.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In this cohort of participants with mild to moderate diabetic neuropathy, elevated triglycerides correlated with MFD loss independent of disease duration, age, diabetes control, or other variables. These data support the evolving concept that hyperlipidemia is instrumental in the progression of diabetic neuropathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/db08-1771","type":"journal-article","created":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T20:45:04Z","timestamp":1241210704000},"page":"1634-1640","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":280,"title":["Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy"],"prefix":"10.2337","volume":"58","author":[{"given":"Timothy D.","family":"Wiggin","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli A.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Pop-Busui","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Amato","sequence":"additional","affiliation":[{"name":"Sigma-Tau Research, Sigma-Tau Pharmaceuticals, Gaithersburg, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders A.F.","family":"Sima","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Neurology, Wayne State University, Detroit, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2009,5,1]]},"reference":[{"key":"2022031210204242400_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.05.005","article-title":"Diabetic neuropathy: Mechanisms to management","volume":"120","author":"Edwards","year":"2008","journal-title":"Pharmacol Ther"},{"key":"2022031210204242400_B2","first-page":"366","article-title":"Somatosensory neuropathy","volume-title":"The Diabetes Mellitus Manual","author":"Feldman","year":"2005"},{"key":"2022031210204242400_B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/138945008783431709","article-title":"Diabetic neuropathy","volume":"9","author":"Feldman","year":"2008","journal-title":"Curr Drug Targets"},{"key":"2022031210204242400_B4","first-page":"606","article-title":"Nerve fiber loss in diabetic neuropathy correlates with impaired evoked potential amplitudes and nerve conduction velocity","volume":"35","author":"Sima","year":"1992","journal-title":"Diabetologia"},{"key":"2022031210204242400_B5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.53.3.580","article-title":"Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group","volume":"53","author":"Greene","year":"1999","journal-title":"Neurology"},{"key":"2022031210204242400_B6","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bmj.39192.488125.BE","article-title":"Skin biopsy: a new tool for diagnosing peripheral neuropathy","volume":"334","author":"Lauria","year":"2007","journal-title":"BMJ"},{"key":"2022031210204242400_B7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2337\/diab.37.4.476","article-title":"Factors in development of diabetic neuropathy: baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT)","volume":"37","author":"The DCCT Research Group","year":"1988","journal-title":"Diabetes"},{"key":"2022031210204242400_B8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/diacare.22.1.99","article-title":"Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial Cohort","volume":"22","author":"Diabetes Control and Complications Trial Cohort","year":"1999","journal-title":"Diabetes Care"},{"key":"2022031210204242400_B9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.5694\/j.1326-5377.1993.tb141332.x","article-title":"The Diabetes Control and Complications Trial (DCCT): a milestone in diabetes management","volume":"159","author":"Chisholm","year":"1993","journal-title":"Med J Aust"},{"key":"2022031210204242400_B10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa032782","article-title":"Vascular risk factors and diabetic neuropathy","volume":"352","author":"Tesfaye","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031210204242400_B11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1046\/j.1464-5491.2002.00821.x","article-title":"Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study","volume":"19","author":"Kempler","year":"2002","journal-title":"Diabet Med"},{"key":"2022031210204242400_B12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/dmrr.806","article-title":"Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention","volume":"24","author":"Steinmetz","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031210204242400_B13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2337\/diacare.28.1.89","article-title":"Acetyl-l-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials","volume":"28","author":"Sima","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031210204242400_B14","first-page":"1","article-title":"Clinical practice recommendations 1995","volume":"18","author":"American Diabetes Association","year":"1995","journal-title":"Diabetes Care"},{"key":"2022031210204242400_B15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-2008-1040975","article-title":"Design of controlled clinical trials for diabetic polyneuropathy","volume":"16","author":"Sima","year":"1996","journal-title":"Semin Neurol"},{"key":"2022031210204242400_B16","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1016\/S0002-9343(99)00008-X","article-title":"New developments in the diagnosis of diabetic neuropathy","volume":"107","author":"Arezzo","year":"1999","journal-title":"Am J Med"},{"key":"2022031210204242400_B17","first-page":"758","article-title":"Peripheral neuropathies","volume-title":"Neuropathology: The Diagnostic Approach","author":"Sima","year":"1997"},{"key":"2022031210204242400_B18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/bioinformatics\/17.6.520","article-title":"Missing value estimation methods for DNA microarrays","volume":"17","author":"Troyanskaya","year":"2001","journal-title":"Bioinformatics"},{"key":"2022031210204242400_B19","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1002\/sim.3182","article-title":"A rank-based sample size method for multiple outcomes in clinical trials","volume":"27","author":"Huang","year":"2008","journal-title":"Stat Med"},{"key":"2022031210204242400_B20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is sochastically larger than the other","volume":"18","author":"Mann","year":"1947","journal-title":"Ann Math Stat"},{"key":"2022031210204242400_B21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0196-0644(05)82571-5","article-title":"Introduction to biostatistics: part 5, statistical inference techniques for hypothesis testing with nonparametric data","volume":"19","author":"Gaddis","year":"1990","journal-title":"Ann Emerg Med"},{"key":"2022031210204242400_B22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00125-006-0169-8","article-title":"Remote neurotrophic support of epidermal nerve fibres in experimental diabetes","volume":"49","author":"Toth","year":"2006","journal-title":"Diabetologia"},{"key":"2022031210204242400_B23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neuroscience.2005.11.065","article-title":"Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin","volume":"139","author":"Toth","year":"2006","journal-title":"Neuroscience"},{"key":"2022031210204242400_B24","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/diacare.27.9.2262","article-title":"Guidelines for computer modeling of diabetes and its complications","volume":"27","author":"American Diabetes Association Consensus Panel","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031210204242400_B25","article-title":"Orange: From Experimental Machine Learning to Interactive Data Mining","volume-title":"Faculty of Computer and Information Science","author":"Demsar","year":"2004"},{"key":"2022031210204242400_B26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1162\/089976699300016304","article-title":"Algorithmic stability and sanity-check bounds for leave-one-out cross-validation","volume":"11","author":"Kearns","year":"1999","journal-title":"Neural Comput"},{"key":"2022031210204242400_B27","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1464-5491.1991.tb01530.x","article-title":"The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy","volume":"8","author":"Veves","year":"1991","journal-title":"Diabet Med"},{"key":"2022031210204242400_B28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0022-510X(95)00243-U","article-title":"Sural nerve myelinated fiber density differences associated with meaningful changes in clinical and electrophysiological measurements","volume":"135","author":"Russell","year":"1996","journal-title":"J Neurol Sci"},{"key":"2022031210204242400_B29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s004010000287","article-title":"Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology","volume":"101","author":"Malik","year":"2001","journal-title":"Acta Neuropathol (Berl)"},{"key":"2022031210204242400_B30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.phrs.2004.04.004","article-title":"Acute hyperglycemia attenuates nerve conduction velocity and nerve blood flow in male Sprague-Dawley rats: reversal by adenosine","volume":"50","author":"Saini","year":"2004","journal-title":"Pharmacol Res"},{"key":"2022031210204242400_B31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1196\/annals.1372.004","article-title":"Diabetic neuropathy differs in type 1 and type 2 diabetes","volume":"1084","author":"Sima","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"2022031210204242400_B32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(71)92415-9","article-title":"Improvement in nerve conduction following treatment in newly diagnosed diabetics","volume":"1","author":"Ward","year":"1971","journal-title":"Lancet"},{"key":"2022031210204242400_B33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","article-title":"Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester diabetic neuropathy study cohort","volume":"49","author":"Dyck","year":"1997","journal-title":"Neurology"},{"key":"2022031210204242400_B34","volume-title":"Clinical Methods: The History, Physical and Laboratory Examinations","author":"Walker","year":"1990"},{"key":"2022031210204242400_B35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.diabres.2007.12.017","article-title":"Risk factors for hospitalization due to diabetes complications","volume":"80","author":"Tomlin","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031210204242400_B36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/diacare.24.2.284","article-title":"Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes","volume":"24","author":"Chaturvedi","year":"2001","journal-title":"Diabetes Care"},{"key":"2022031210204242400_B37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11892-007-0041-3","article-title":"Oxidative stress and endothelial dysfunction in vascular disease","volume":"7","author":"Pennathur","year":"2007","journal-title":"Curr Diab Rep"},{"key":"2022031210204242400_B38","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.metabol.2003.10.009","article-title":"Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes","volume":"53","author":"Tsuzura","year":"2004","journal-title":"Metabolism"},{"key":"2022031210204242400_B39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1056-8727(01)00140-4","article-title":"Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes","volume":"15","author":"Fried","year":"2001","journal-title":"J Diabetes Complications"},{"key":"2022031210204242400_B40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00125-007-0919-2","article-title":"Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study","volume":"51","author":"Davis","year":"2008","journal-title":"Diabetologia"},{"key":"2022031210204242400_B41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/mus.20423","article-title":"Sural sensory action potential identifies diabetic peripheral neuropathy responders to therapy","volume":"32","author":"Vinik","year":"2005","journal-title":"Muscle Nerve"},{"key":"2022031210204242400_B42","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2337\/diacare.29.02.06.dc05-2177","article-title":"Objective evidence for the reversibility of nerve injury in diabetic neuropathic cachexia","volume":"29","author":"Grewal","year":"2006","journal-title":"Diabetes Care"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/58\/7\/1634\/394578\/zdb00709001634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/58\/7\/1634\/394578\/zdb00709001634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:18:15Z","timestamp":1667391495000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/58\/7\/1634\/15679\/Elevated-Triglycerides-Correlate-With-Progression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,1]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,5,1]]},"published-print":{"date-parts":[[2009,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db08-1771","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,1]]}}}